SRPT · Healthcare
Sarepta Therapeutics Inc
24/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
32
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$1.9B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About SAREPTA THERAPEUTICS INC
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in…
Who's behind the signal
Every informed buyer we can see on SRPT, across all three feeds.
Hedge funds · 6
Millennium Management (Englander)
Increased +22%
Citadel Advisors
Increased +449%
AQR Capital Management
Decreased −18%
Bridgewater Associates (Dalio)
Decreased −52%
D.E. Shaw & Co
Decreased −69%
Gotham Asset Mgmt (Greenblatt)
Decreased −79%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 4 on record
Disclosures from 2019-12-13 to 2020-11-06
The newest disclosure we hold for this stock is 2020-11-06.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2020-11-06 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2020-09-14 | Gilbert Ray Cisneros, Jr. · D-CA | House | Bought | $1,001 - $15,000 |
| 2020-06-10 | Gilbert Ray Cisneros, Jr. · D-CA | House | Sold | $1,001 - $15,000 |
| 2019-12-13 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
Not a model pick — but on our radar.
SAREPTA THERAPEUTICS INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
2
Increasing
4
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+22%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+449%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−18%
0.1% of AQR Capital Management's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
−52%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−69%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−79%
0.0% of Gotham Asset Mgmt's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to SAREPTA THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell SAREPTA THERAPEUTICS INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订